Grace Therapeutics, Inc. 8-K
Research Summary
AI-generated summary
Grace Therapeutics Files 8-K Reporting Results of Operations
What Happened
Grace Therapeutics, Inc. (GRCE) filed a Form 8-K on February 12, 2026 under Item 2.02 to furnish information regarding its results of operations and financial condition. The company attached a press release dated February 12, 2026 as an exhibit to the filing.
Key Details
- Filing date: February 12, 2026 (Form 8-K, Item 2.02).
- Exhibit: Press release dated February 12, 2026 furnished as Exhibit 99.1.
- Interactive XBRL cover page included (Exhibit 104).
- The 8-K furnishes results of operations/financial condition information; investors should review the press release for the specific earnings, revenue, or quarterly results figures.
Why It Matters
This filing notifies investors that Grace Therapeutics has publicly released updated financial information (earnings/operational results). For retail investors, the press release is the primary source for any changes in revenue, earnings, guidance, or other financial metrics that could affect the stock. Review the attached press release and the company’s subsequent periodic filings (10-Q/10-K) for the full financial details and context.